Atty Dkt. No.: UCAL-282 USSN: 10/626.415

I. AMENDMENTS

IN THE CLAIMS

Cancel claims 5-20 without prejudice to renewal.

Please enter the amendments to claims 1, 21, and 24-27, as shown below.

1. (**Currently amended**) A composition comprising an isolated apolipoprotein E (apoE) stable folding intermediate, wherein the apoE stable folding intermediate is at least [[about]] 80% pure, wherein the apoE is apoE3 or apoE4, and wherein the stable folding intermediate is formed at a pH of from [[about]] 1.0 to [[about]] 5.0.

2. (Canceled)

- 3. (Previously presented) The composition of claim 1, wherein the apoE stable folding intermediate comprises an N-terminal fragment of apoE4.
- 4. (Original) The composition of claim 3, wherein the N-terminal fragment of apoE4 is about 22 kDa in size.

5.-20. (Cancelled)

- 21. (**Currently amended**) The composition of claim 1, wherein the apoE stable folding intermediate is at least [[about]] 90% pure.
- 22. (Previously presented) The composition of claim 1, wherein the apoE stable folding intermediate comprises an N-terminal fragment of apoE3.
- 23. (Previously presented) The composition of claim 22, wherein the N-terminal fragment of apoE3 is about 22 kDa in size.

Atty Dkt. No.: UCAL-282

USSN: 10/626,415

24. (**Currently amended**) The composition of claim 1, wherein the apoE stable folding intermediate is formed at a pH of from [[about]] 2.0 to [[about]] 4.0.

- 25. (**Currently amended**) The composition of claim 1, wherein the apoE stable folding intermediate is formed at a urea concentration of from [[about]] 2M to [[about]] 7M.
- 26. (**Currently amended**) The composition of claim 1, wherein the apoE is apoE4, and wherein the apoE stable folding intermediate is formed at a urea concentration of from [[about]] 3.5 M to [[about]] 4.5 M.
- 27. (**Currently amended**) The composition of claim 1, wherein the apoE is apoE3, and wherein the apoE stable folding intermediate is formed at a urea concentration of from [[about]] 4.5 M to [[about]] 5 M.